Eli Lilly makes surprising retreat from major market

U.K. politicians later agreed to pay 25% more for new medicines to avoid U.S. tariffs on pharma. Germany now faces a similar test.

President Trump’s Most Favored Nation (MFN) pricing proposals add another layer.

By tying proposed U.S. drug prices to what companies charge in countries like Germany, pharma companies cannot yield to European pricing pressure without eroding their largest market, BioSpace noted.

Where the money is going instead

The redirected capital flows into a U.S. manufacturing strategy that was already moving fast.

In January 2026, Lilly announced a $3.5 billion facility in Fogelsville, Pennsylvania, the fourth new U.S. site since February 2025 and the largest life sciences investment in Pennsylvania’s history, according to the Pennsylvania Governor’s office.

That site capped a broader commitment:

Lilly pledged at least $27 billion across four new U.S. plants in February 2025, pushing its total U.S. manufacturing investment past $50 billion in recent years, CNBC reported.

What the Germany retreat signals for LLY investors

A few things worth keeping in mind before drawing conclusions:

• The Alzey plant will still open in 2027 at reduced capacity, meeting Lilly’s “minimum supply commitments to patients in Germany,” so near-term supply disruption looks limited.

• Lilly left the door open on future German expansion, but only if policymakers restore a “stable, predictable economic framework.”

• However, because U.S. manufacturing costs run structurally lower than European equivalents, bolstered by lower energy costs and superior productivity, Lilly is shifting its remaining capital back to the U.S.

• This dynamic, combined with intensifying political pressure to lower drug prices globally, threatens to squeeze margins unless the company can successfully raise commercial drug prices across its remaining European markets.

What this means for LLY stock

Lilly enters this news from a position of strength.

First-quarter 2026 revenue reached $19.8 billion, up 56% year over year, driven by Mounjaro and Zepbound, which together generated $12.8 billion in combined global Q1 revenue, according to Lilly’s official Q1 earnings report.

Management raised full-year 2026 revenue guidance to $82 billion to $85 billion.

According to S&P Global data cited by StockAnalysis, 31 analysts carry a consensus Buy rating on LLY, with an average 12-month price target of $1,215, implying roughly 10% upside from late May levels.

Deutsche Bank carries a Buy rating with a $1,200 target.

LLY shares have gained approximately 42% over the past year, compared to a 27% return for the S&P 500 over the same period, according to Yahoo Finance data.

The Germany retreat does not threaten Lilly’s core growth story, but it signals a clear strategic shift: capital is flowing to where the policy environment welcomes it, and right now, that is the U.S.

The GLP-1 franchise and the pipeline remain the primary investment thesis for LLY, and neither is changed by what happened in Alzey.

Related: 245-year-old pharma giant cuts 4,500 jobs amid legal troubles

This story was originally published by TheStreet on Jun 6, 2026, where it first appeared in the Investing section. Add TheStreet as a Preferred Source by clicking here.